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Genetically modified cells of haematopoietic and lymphocytic lineages could provide potentially
curative treatments for a wide range of inherited and acquired diseases. However, this application
is limited in mouse models by the low efficiency of lentiviral vectors. To facilitate the rapid
production of high-titre helper-free retroviral vectors for enhanced gene delivery, multiple
modifications to a prototype moloney murine leukemia virus (MoMLV)-derived vector system were
made including adaptation of the vector system to simian virus 40 ori/T antigen-mediated
episomal replication in packaging cells, replacement of the MoMLV 59 U3 promoter with a series
of stronger composite promoters and addition of an extra polyadenylation signal downstream of
the 39 long terminal repeat. These modifications enhanced vector production by 2–3 logs. High-
titre vector stocks were tested for their ability to infect a variety of cells derived from humans and
mice, including primary monocyte-derived macrophage cultures. Whilst the lentiviral vector was
significantly restricted at the integration level, the MoMLV-based vector showed effective gene
transduction of mouse cells. This high-titre retroviral vector system represents a useful tool for
efficient gene delivery into human and mouse haematopoietic and lymphocytic cells, with
particular application in mice as a small animal model for novel gene therapy tests.
INTRODUCTION
Retroviral vector-mediated gene therapy is a promising
approach for treating human diseases. Initial attention has
centred on candidate diseases affecting bone marrow, such
as haemoglobinopathies and severe combined immunode-
ficiencies (Culver et al., 1991). Theoretically, diseases aside
from those affecting bone marrow could also be treated
with haematopoietic cells transduced with therapeutic
genes. For instance, the appearance and activation of
macrophages are thought to be rapid events in the
development of many pathological lesions. This has
prompted recent attempts to use macrophages as novel
cellular vehicles for gene therapy (Dou et al., 2006, 2009).
Macrophages are genetically modified ex vivo and reintro-
duced into the body in the hope that a significant portion
will then migrate to the afflicted site (Burke et al., 2002).
Alternatively, lymphocytes have several features that make
them attractive, as they are readily available and easily
manipulated in tissue culture, which permits time for
selection and testing for gene expression before infusion
into the patient (Culver et al., 1991). As a result, there is an
increasing interest in the development of efficient methods
for gene delivery into haematopoietic and lymphocytic cells
such as primary macrophages, lymphocytes and derivative
cell lines (Clay et al., 1999; Gough & Raines, 2003; Okasora
et al., 2008; Roszkowski et al., 2005; Wilson & Kluth, 2003).
Retroviral vectors have been tailored for over 20 years as a
means of corrective therapy, as well as tools for research
(Cockrell & Kafri, 2003). In recent decades, however, low
transduction efficiencies have limited the clinical applica-
tion of most transduction protocols, and results of the
majority of human haematopoietic- and lymphoid-cell
gene therapies have been largely disappointing (Ayuk et al.,
2001; Hawley, 2001), paralleled with the limited success
achieved in preclinical gene transfer studies in non-human
primates and human haematopoietic stem cells in xeno-
genic transplant assays (Donahue et al., 1996). Fortunately,
gene therapy has recently had some important successes in
treating severe inherited diseases (Aiuti et al., 2009; Cartier
et al., 2009; Fischer & Cavazzana-Calvo, 2008; Miller, 2008)
after years of scepticism from the scientific community and
neglect by the pharmaceutical industry (Naldini, 2009).
Two trials have indicated successful clinical testing using
retroviral (Aiuti et al., 2009) and lentiviral (Cartier et al.,
2009) vectors, respectively, in haematopoietic stem cell-
based gene therapy.
Murine primary cells are poorly permissive to lentiviral
vector infection (Noser et al., 2006). Therefore, it would be
of particular interest to establish a high-titre retroviral
vector system for the development of mouse models for
gene therapy tests. In this report, multiple strategies aimed
at the production of high-titre Moloney murine leukemia
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evaluated. Vectors derived from the modified system were
tested on a wide array of cell types and indicated improved
efficiency of gene delivery into cells from both humans and
mice.
RESULTS
Enhanced vector titres by multiple modifications
To boost vector titres from a prototype MoMLV-based
vector system so that effective transduction of target cells
could be achieved, multiple modifications to the transfer
plasmids were tested and evaluated (see Methods). As
shown in Fig. 1(a), these modifications included adapta-
tion of an SV40 ori into the backbone, replacement of the
59 native MoMLV U3 promoter with a series of
heterologous and/or composite promoters, and the addi-
tion of an extra SV40 polyadenylation signal downstream
of the 39 long terminal repeat (LTR). The adaptation of
SV40 ori not only raised the vector titre by more than
tenfold [from 2.8610
5 to 3.8610
6 infection units (IU)
ml
21, Fig. 1b, P,0.001], but also effectively extended
the temporal vector production to more than 10 days
compared with 4 days for the original construct (data not
shown). Furthermore, addition of the SV40 poly(A) alone
roughly doubled the vector titres, whilst the human
cytomegalovirus (CMV) promoter replacement alone
increased the vector titre by fourfold. Together, these two
modifications resulted in an approximately tenfold increase
in vector production, with an absolute titre of more than
3.0610
7 IU ml
21 (Fig. 1b).
To maximize vector titres further, two composite hybrid
promoters were constructed and evaluated. As shown in
Fig. 1(a), two strategies were employed. One was to
strengthen the CMV promoter with two enhancers from
SV40 and human respiratory syncytial virus (RSV)
promoters; the other was to strengthen the MoMLV U3
promoter with a combination of three enhancers from
SV40, RSV and CMV promoters. Titres derived from the
modified plasmids indicated that strengthening the
MoMLV U3 promoter with enhancers from SV40, RSV
and CMV promoters increased the titre from 5.47610
6 to
2.32610
7 IU ml
21, a greater than fourfold increase, whilst
strengthening the CMV promoter with enhancers from
SV40 and RSV promoters elevated vector production from
2.89610
7 to 4.52610
7 IU ml
21 (Fig. 1b, P,0.001).
Overall, the transfer plasmid containing the CMV pro-
moter strengthened with enhancers from SV40 and RSV
promoters demonstrated the highest titre vector produc-
tion (P,0.001). Based on this plasmid, two self-inactiv-
ating (SIN) vectors (Fig. 1a) were generated and tested. As
Fig. 1. High-titre vector production boosted by multiple modifications. (a) Maps of transfer vectors with multiple modifications.
SIN vectors contained 39 self-inactivating LTRs as a result of the deletion of the U3 promoter. eGFP, Enhanced GFP; pA
poly(A); pre, post-transcriptional regulatory element; pro, promoter; psi, Y domain; R, repeat region of the LTR; SF, spleen
focus-forming virus U3 promoter; SRC, combination of enhancers from SV40, SRV and CMV promoters; SRCMV, hybrid
promoter with CMV promoter strengthened with enhancers from SV40 and RSV promoters; S-RSV, hybrid promoter with RSV
promoter strengthened with enhancer from SV40 promoter. (b) Vector titres derived from the plasmids in (a). Supernatants were
collected on day 3 post-transfection and titrated in CEM-SS cells. The titres presented were derived from representative
experiments with three replicates (mean±SD). ***, P¡0.001.
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SF-GFPpre plasmid, pSR-CMV-MLV-SIN increased the
titre from 1.31610
7 to 1.97610
7 IU ml
21, and pSR-CMV-
SV-MLV-SIN-polyA further boosted the titre to 3.09610
7
IU ml
21. Overall, these modifications stimulated titres
nearly three times higher than the original SIN plasmid.
Vector concentration and biosafety assay
As shown in Table 1, MoMLV-based vector titres were
increased significantly by over 200 times (from
1.57±0.11610
7 IU ml
21 to 4.22±0.22610
9 IU ml
21)
following a one-step ultracentrifugation, and titration tests
demonstrated a recovery efficiency of approximately 90%,
which is comparable to that of human immunodeficiency
virus type 1 (HIV-1)-based vectors (Zeng et al., 2006).
Through this concentration protocol, a helper virus assay
was performed with no detection of any replication-
competent virus. To meet the US Food and Drug
Administration requirement that clinical vector material
generated in 293T cells should be tested for whether there
is transfer of SV40 sequences to the target cells, PCR-based
tests specific for the SV40 T antigen (SV40T) and SV40 ori
sequences showed that there was a detectable amount of
transfer of SV40 ori into the supernatant collected from the
producer cells, but this sequence was not further
transferred into target cells. In addition, there was no
detection of the SV40T sequence in either the supernatant
or the target cells (Fig. 2).
Differential transduction of human- and mouse-
derived cells
Based on high-titre vector preparations from the multi-
modified system, the titration sensitivity of the modified
vector was tested in various cell types originating from
humans and mice, with two types of HIV-1-based lentiviral
vectors titrated in parallel for comparison (Fig. 3a). As
shown in Fig. 3(b), HIV-1-based vectors showed high
efficiencies in transducing cell lines derived from humans,
except for pHR-cPPT in CEM-SS cells, which may be due
to differences in the usage of promoters. However, both
HIV-1-based vectors were found to be much less efficient
at transducing mouse cells. When the same vector
preparation was titrated, HIV-1-based vectors showed an
infectious titre of .10
7 IU ml
21 in human cells, whilst the
infectious titre of this vector stock dropped to 10
4 IU ml
21
in mouse cells, with the lowest vector titre of 10
3 IU ml
21
in RAW 264.7 cells. In sharp contrast, the modified
MoMLV-based system showed comparable titres when
used to infect these same human and mouse cells. As
shown in Fig. 3(b), CEM-SS, NIH3T3 and PA317 cells were
the most susceptible to MoMLV-based vectors, whilst
RAW 264.7 cells were the least, although the difference in
apparent titres was less than tenfold.
This dramatic difference in the transduction of mouse cells
was further confirmed using concentrated vectors for
transduction. As shown in Fig. 3(c), MT-2, BV-2, TIB-100
and RAW 264.7 cells were tested in parallel with these three
types of vector using the same m.o.i. of 100. Transduction
efficiencies were determined on day 3 post-infection (p.i.).
MT-2 cells were confirmed to be the most susceptible to all
three vectors, whilst the other three mouse cell lines were
susceptible to MoMLV-based vectors but refractory to
HIV-1-based vectors. As evaluated by the percentage of
green fluorescent protein (GFP)-positive cells, the
MoMLV-based vector demonstrated over 90% transduc-
tion efficiency in all cell types tested; HIV-1-based vectors,
however, showed a high transduction efficiency only in the
human-derived MT-2 cells, and lower transduction
efficiencies in the mouse-derived BV-2 and RAW 264.7
Fig. 2. PCR-based detection of transfer of SV40 ori and SV40T
sequences. Lane M, 100 bp DNA ladder (New England Biolabs);
lanes 1 and 6, negative controls using ddH2O; lanes 2 and 7,
templates of 50 ng DNA from transfected 293T producer cells as
positive controls; lanes 3 and 8, 1 ml supernatant collected from
293T producer cells used as template to detect SV40 sequences;
lanes 4 and 9, templates of 50 ng DNA extracted from transduced
CEM-SS cells to detect the transfer of SV40 sequences into
target cells.
Table 1. Vector concentration by single-step ultracentrifuga-
tion
Vector titres were determined on 293T cells.
Vector Unconcentrated
(IU ml
”1)*
Concentrated
(IU ml
”1)
% Recovery
MoMLV (1.57±0.11)610
7 (4.22±0.22)610
9 89.48±3.08
DHIV-101 (1.55±0.10)610
7 (4.34±0.27)610
9 93.33±0.89
HR-cPPT (5.86±0.41)610
6 (1.49±0.13)610
9 84.46±1.39
*Vector-containing supernatant was collected every 24 h for 3 days
post-transfection from a representative transfection experiment,
which was performed in triplicate for each vector type.
Retroviral vector for mouse cell gene transduction
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cells (Fig. 3c).
Characterization of transduction with semi-
quantitative PCR
To examine the potential cause making mouse-derived cells
less susceptible to stable transduction with HIV-1-based
lentiviral vectors, a semi-quantitative PCR assay was
performed. As shown in Fig. 4(a), infection of the human
lymphocyte-derived cell line CEM-SS resulted in a transduc-
tion efficiency of greater than 95%, as indicated by the
percentage of GFP-positive cells, using both the MoMLV-
and HIV-1-based vectors. In the mouse-derived macro-
phage cell line, however, infection with the MoMLV-based
vector showed 74.25% transduction efficiency, but the HIV-
1-based lentiviral vector showed only 9.32% GFP-positive
cells. To examine the possibility that the decreased
transduction efficiency by the lentiviral vector was caused
by inhibition of genome conversion following infection,
DNAwasextractedfrom infectedcellsandanalysed bysemi-
quantitative PCR. As shown in Fig. 4(b), DNAs from RAW
264.7 cells infected with both types of vector had similar
levels of proviral DNA, as indicated by the GFP gene, on day
1 p.i. However, following a longer period of cultivation up
to day 10 p.i., only DNAs extracted from the MoMLV-based
vector-infected cells maintained similar levels of the GFP
gene. Whilst there was no apparent difference in viability,
morphology or growth of the transduced cells with either
vector type, extended cultivation led to a dramatic decrease
Fig. 3. Titration sensitivity test for MoMLV-based vectors in comparison with HIV-1-based counterparts. (a) Maps of vector
constructs used for the test. pSR-CMV-SV-N2A-GFP-polyA, Modified MoMLV vector; pDHIV-101, defective HIV-1-based
transfer construct expressing Tat, Rev and Vpu accessory proteins; pHR-cPPT, fully gutted HIV-1-based transfer construct
using an internal CMV promoter (CMV Pro) for transgene expression, with eGFP mediated by an internal ribosome entry site
element. cPPT, Central polypurine tract; RRE, Rev response element; for other abbreviations, see Fig. 1 legend. (b) Titres in
ten cell lines from human and mouse. (c) Transduction efficiency in representative cell lines using concentrated vector.
*, 0.01,P¡0.05; ***, P¡0.001.
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the HIV-1-based vector-infected cells. Although MoMLV-
based vector-infected cells also showed some degree of
decline in the level of the GFP gene at 10 days p.i., the
decrease was less than tenfold.
To characterize further the step in the transduction process
at which a block is encountered following reverse
transcription in mouse cells, episomal 2-LTR circles (a
by-product of HIV-1 infection) were analysed as markers
for nuclear import of the pre-integration complex.
Following comparable levels of reverse transcription (Fig.
4b), levels of 2-LTR circles were found to be similar in
comparison. This suggested efficient nuclear import of the
HIV-1-based vector pre-integration complex in mouse cells
relative to the human counterpart, and that the processes
of reverse transcription and nuclear import were not
blocked in the tested mouse cells.
High-efficiency transduction of murine bone
marrow-derived monocytes/macrophages
To facilitate the use of laboratory mice as a small animal
model for gene therapy studies, concentrated MoMLV-
based vector preparations, together with two of the newly
constructed MoMLV- and HIV-1-based SIN vectors (Fig.
1a and Fig. 5a), were tested for their efficiency in
transducing primary cultures of mouse monocyte-derived
macrophages (MDMs). Another defective HIV-1 construct,
pDHIV-101, and an adenovirus-based vector were also
Fig. 4. Vector transduction characterized by semi-quantitative PCR. (a) Differential transduction efficiencies with MoMLV- and
HIV-1-based vectors. Cells were infected as described in Methods and the percentage of GFP-positive cells was determined
on day 10 p.i. ***, P¡0.001. (b) Semi-quantitative PCR detection of DNA from RAW 264.7 cells infected with MoMLV- and
HIV-1-based vectors. The upper panels are GFP-specific amplifications, whilst the lower panels show b-actin-specific
amplification as a control of the amount of template. Lane M, 50 or 100 bp ladder (NEB); lane P, positive control; lane W,
negative control (H2O). (c) Semi-quantitative PCR detection of 2-LTR circle junctions. DNAs from CEM-SS or RAW 264.7
cells infected with MoMLV- or HIV-1-based vectors were diluted and used as templates for PCRs as described in Methods.
Lane M, HyperLadder I (Bioline); lane C, negative control with 20 ng DNA from mock-transduced cells.
Retroviral vector for mouse cell gene transduction
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(a)
Fig. 5. High-efficiency transduction of primary monocytes/macrophages. (a) Map of the SIN lentiviral construct used for
transduction; maps for the other transfer constructs are presented in Fig. 1(a), and the adenovirus vector was derived as
described in Methods. CMV Pro, CMV promoter; WPRE, woodchuck hepatitis virus post-transcriptional regulatory element; for
other abbreviations, see Fig. 1 and Fig. 3 legends. (b) Transduction of mouse primary MDMs derived from bone marrow at
various m.o.i. as indicated, along with HIV-1- and adenovirus-based vectors as indicated. MLV SIN, pSR-CMV-SV-MLV-SIN-
polyA; HIV SIN, pHR-cPPT-hB.7-SIN. Representative microphotographs were taken on day 3 p.i. FL, Fluorescent light; NL,
normal light. (c) Transduction efficiencies from the infections described in (b). The percentage of GFP-positive cells was
counted on day 3 p.i., and means±SD are presented.
C. Wu and Y. Lu
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contained three of the HIV-1 accessory genes. However,
rather than the other fully gutted HIV-1-based SIN vector,
pHR-cPPT-hB.7-SIN (Fig. 5a), it was this first-generation
vector construct that indicated efficient transduction of
mouse MDMs (Fig. 5b, c). As shown in Fig. 5(b, c), the
efficiency of MoMLV-based vector-mediated transduction
of primary mouse MDMs was directly correlated to vector
m.o.i. At an m.o.i. of 5, approximately 4.67% of the cells
appeared to be GFP-positive, whilst at an m.o.i. of 100, up
to 68% of the cells appeared to be GFP positive from a
single infection. This efficiency was comparable to that of
the first-generation lentiviral control, which was 77.95%
for DHIV-101 at an m.o.i. of 100. When the adenovirus-
based vector was applied at the same m.o.i., however, only
3.34% of the cells were GFP positive, showing that primary
mouse MDMs are much less sensitive to infection through
the adenoviral vector.
Similarly, the MoMLV-based SIN vector showed high
transduction efficiency in the mouse MDMs, with 60.13%
GFP-positive cells at an m.o.i. of 100. The HIV-1-based
SIN vector, however, resulted in only 8.33% GFP-positive
cells when infected at an m.o.i. of 100, which was
significantly lower than that of the MoMLV-based vector
counterpart.
DISCUSSION
In this study, standard molecular biology techniques were
used to achieve enhanced production of high-titre retro-
viral vectors, and improved vector preparations were tested
for high-efficiency gene transduction of various cell types
from human and mouse. Overall, the described modifica-
tions gradually increased the vector titres by 2–3 logs, as
well as giving high-titre production of SIN vectors.
Collectively, the described modifications imply that vector
production could be much less laborious and more
economically effective, as well as providing large quantities
of high-quality vectors for certain demanding applications,
such as the in vivo transfer of genes into haematopoietic
cells (McTaggart & Al-Rubeai, 2002). Furthermore, this
modified system supported improved vector production
for up to 10 days without the apparent death of the
producer cells, thus minimizing the release of toxic factors
from dying cells into the supernatant. Consequently, this
minimizes the negative effect on the target cell populations.
As demonstrated in Fig. 5(b), the primary mouse MDMs
had no apparent effect on cellular viability or morphology
after extended cultivation following infection, indicating
that the vector preparations used were free of notable
cytotoxic contaminating factors, which supports the
potential use of these vectors for in vivo studies.
Moreover, high-efficiency concentration, together with no
detectable generation of replication-competent virus or
transfer of SV40 sequences into the target cells, indicates
that this vector system would be a suitable tool for
protocols utilizing high titres, as well as satisfying the
requirements for high biosafety standards, such as for in
vivo applications.
In addition to high titres, gene delivery into a broad range
of cells is important for potential applications. For this
reason, vectors from the modified system were tested on a
series of cell types derived from humans and mice in
comparison with two HIV-1-based vectors. Interestingly,
the MoMLV-based vectors were capable of efficient
infection of both human and mouse cells, indicating that
they were not restricted by cell type. In contrast, HIV-1-
based vectors showed high efficiency in human cells but
significantly reduced infectivity in mouse cells. Possible
reasons for this phenomenon were examined by semi-
quantitative PCR tests of the reverse transcription product,
as well as its persistence in the dividing cells and the
formation of 2-LTR circle junctions. The results suggested
that, following HIV-1 virion entry mediated by the pan-
tropic vesicular stomatitis virus G protein, reverse
transcription occurred efficiently in RAW 264.7 cells, but
the resultant proviral DNAs failed to persist for the
extended culture time of the infected cells. In addition, a
comparable level of 2-LTR circles was detected, which
suggested efficient import of the HIV-1 pre-integration
complex into the nucleus. These results might allow
mapping of the transduction block in RAW 264.7 cells to
some event following nuclear entry and after the formation
of 2-LTR circle junctions, but before the successful
integration event. Theoretically, high-efficiency transduc-
tion of mouse MDMs by the first-generation HIV-1 vector
DHIV-101 could be facilitated by any of the three accessory
genes, among which Vpu is the most likely responsible
factor, as Vif and Vpu are known to counteract the
antiviral effects of cellular restrictions to early and late steps
in the virus replication cycle (Sharova et al., 2008). This
gene, however, should be clarified, as it may not be
desirable for gene therapy vectors due its side effects and
biosafety concerns.
Although the MoMLV vector is considered unsuitable for
transduction of dormant or resting cells, this can be
overcome by recent advances, such as the present
application of macrophage colony stimulating factor, or
controlled cell-expansion techniques (May et al., 2009). As
demonstrated in Fig. 5(b, c), MoMLV vectors proved to be
effective transducers of primary MDMs in a single
infection. This is particularly important, as conduction of
in vivo experiments and data from animal tests depend
largely on efficient transduction of primary cells.
Furthermore, the ability to transduce most cells through
a single infection could avoid cell selection procedures and
allow immediate transplantation of transduced cells,
representing another advantage of using a high-titre vector
system. With encouragement from the recent advances in
successful clinical trials using retroviral vectors (Aiuti et al.,
2009), the development of retroviral vectors for superior
gene delivery into mouse cells, especially cells of haema-
topoietic and lymphocytic origin, may be of particular
significance. The system constructed through this study is a
Retroviral vector for mouse cell gene transduction
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observed in human cells.
In summary, a low-titre MoMLV-based vector system was
effectively improved through a series of modifications,
which led ultimately to elevated vector titres of more than
4.5610
7 IU ml
21. It was also demonstrated that the
MoMLV vectors were highly infective to cells derived from
both humans and mice. Overall, this vector system could
serve as a valuable tool for efficient gene delivery into a
wide range of cells, including primary murine cells, during
gene therapy trials using mice as a small animal model.
METHODS
MoMLV-based transfer plasmid construction. All parental
plasmids used in this research, unless specified otherwise, for
MoMLV- and HIV-1-based vector systems were from Dr Vicente
Planelles (University of Utah, UT, USA). An SV40 ori-containing
fragment was cut from pDHIV-3 by SmaI and PvuI, blunted using
Klenow fragment and ligated into pN2A-GFP cut by HindIII and
NdeI and blunted. The resultant plasmid was named pSV-N2A-GFP.
The SV40 poly(A) tail was amplified by PCR using primers 59-
TTGTTGTTAACTTGTTTATTGCAG-39 (forward) and 59-GAGTTT-
GGACAAACCACAAC-39 (reverse) from pmRFP-N (Campbell et al.,
2002) and ligated into the blunted SpeI site of pSV-N2A-GFP. The
resultant plasmid was named pSV-N2A-GFP-polyA. To replace the 59
MoMLV U3 promoter with the CMV promoter, the CMV promoter
was amplified from pmRFP-N1 with primers 59-GCGCGATGC-
ATCCGTATTACCGCCATGC-39 (forward) and 59- GTCAATCGG-
AGGACTGGCGCGGTTCACTAAACCAGC-39 (reverse; underlined
sequence overlaps the R region of the 59 LTR). The second fragment
from pN2A-GFP, including R, U5 and the packaging signal, was
amplified with 59-CGCCAGTCCTCCGATTGAC-39 (forward) and
59-GCGCGATGCATCGTTCCACTGAGCGTCAG-39 (reverse). The
products were used as templates for fusion PCR with the forward
primer of the first PCR and the reverse primer of the second PCR.
The fusion PCR product was digested with NsiI and BsrGI and ligated
into pSV-N2A-GFP and pSV-N2A-GFP-polyA between NsiI and
BsrGI. The resultant plasmids were named pCMV-N2A-GFP and
pCMV-N2A-GFP-polyA. A fragment containing the enhancers from
the SV40 and RSV promoters was amplified from pSERS11-SF-
GFPpre (Schambach et al., 2006) (obtained from Dr Christopher
Baum, Hannover Medical School, Germany) with 59-GTTTGCG-
CAACGTTGTTGCCATT-39 (forward) and 59-GGGAATTCAGTGG-
TTCGTCCAATC-39 (reverse). The PCR product was cloned into
pCR-4-TOPO (Invitrogen), cut with FspI and EcoRI, blunted and
ligated into pCMV-N2A-GFP-polyA cut with FspI and NsiI and
blunted. The resultant plasmid was named pSR-CMV-SV-N2A-GFP-
polyA. A fragment containing the combination of SV40, SRV and
CMV enhancers was released from pSR-CMV-SV-N2A-GFP-polyA by
FspI and SnaBI, and ligated with the 5938 bp fragment from pSV-
N2A-GFP-polyA cut by FspI, followed by a partial cut with NheI, and
blunted. The resultant plasmid was named pSRC-MLV-SV-N2A-
GFP-polyA. A fragment containing the internal promoter, GFP gene
and 39 SIN LTR was released from pSERS11-SF-GFPpre by BglII and
XhoI digestion and ligated into pSR-CMV-SV-N2A-GFP-polyA cut
with BamHI and XhoI. The resultant plasmid was either cut with XhoI
and SacI with self-ligation to generate pSR-CMV-SV-MLV-SIN-
polyA, or with XhoI and BsaXI to generate pSR-CMV-MLV-SIN.
MoMLV-based packaging plasmid construction. The MoMLV R
region and a portion of the gag gene was amplified from pSVy
2-
MLV-Env
2 (Landau & Littman, 1992), fused with the CMV promoter
and cloned into pSV-N2A-GFP. The resultant plasmid, named
pCMV-y
2-N2A-GFP-polyA, was cut with BsrGI and NheI, and
ligated with the gag–pol gene released from pSVy
2-MLV-Env
2 with
BsrGI and NheI. The resultant plasmid was named pCMV-y
2-MLV-
Env
2.
HIV-1-based transfer plasmid construction. A fragment contain-
ing CMV-hB7.1-IRES-GFP elements was cut with HaeII and AccI
from plasmid pHR-hB7.1-IRES-GFP, blunted and ligated into
pDHIV-101 cut with EcoRI and XbaI and blunted. The resultant
plasmid was named pHR-cPPT. The fragment containing the CMV-
hB7.1-IRES-GFP elements was released from pHR-hB7.1-IRES-GFP
with ClaI and BsrGI, blunted and ligated into pFG12 (Qin et al., 2003)
(obtained from Dr David Baltimore, California Institute of
Technology, CA, USA), which had been cut with XhoI and BsrGI
and blunted. The resultant plasmid was named pHR-cPPT-hB.7-SIN.
Culture of cell lines. Human embryonic kidney cells (293T), human
neuroblastoma cells (HTB-11) and two mouse fibroblast cell lines
(NIH3T3 and PA317) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM; Sigma) containing 1000 mg glucose l
21 and
4.0 mM L-glutamine (Sigma). Two human T-lymphocyte cell lines,
CEM-SS and MT-2, were maintained in RPMI 1640 (Sigma). One
human microglia cell line (CHME) and three murine cell lines [BV-2
(microglia), RAW 264.7 (macrophage) and TIB-100 (B lymphocyte)]
were maintained in DMEM with 4500 mg glucose l
21 and 4.0 mM L-
glutamine. All cell culture media were supplemented with 10% heat-
inactivated fetal bovine serum (HyClone), 100 U penicillin ml
21
(Sigma) and 100 mg streptomycin sulfate ml
21 (Sigma). Cells were
maintained at 50–70% confluency in a humidified 37 uC incubator
with 5% CO2 and split at a 1:2–4 ratio every 3–4 days.
Primary culture of monocytes and macrophages from mouse
bone marrow. Adult CD-1 mice were purchased from Charles River
Laboratories and housed at the University of Hawaii at Manoa School
of Medicine Animal Facility until used in experiments. All animal
procedures were approved by the Animal Care and Use Committee of
the University of Hawaii at Manoa. Mouse bone marrow-derived
MDMs were isolated and maintained as described previously (Wirth
et al., 1982; Zeng et al., 2006), with the addition of 1000 U
macrophage colony-stimulating factor ml
21 (obtained from Dr
Howard Gendelman, University of Nebraska, NE, USA) to the
growth medium.
Vector production and concentration. Vectors were produced as
described previously (Wu & Lu, 2007). Vector-containing supernat-
ant was collected every 24 h and either used for titration or
concentrated by ultracentrifugation, as described previously (Zeng
et al., 2006). The recovered vector was resuspended in serum-free
DMEM, pooled, aliquotted at 100–200 ml per vial and stored at
280 uC until used. Adenovirus-based vector was prepared and
aliquotted as described previously (Wu et al., 2008). Titration of the
vectors was performed as described previously (Wu & Lu, 2007),
except that the optimal medium for each cell type was used.
Helper virus and transfer of SV40 sequence assays. Helper virus
assays were performed as described previously (Pear et al., 1993;
Soneoka et al., 1995) with minor modifications. Briefly, 200 ml
concentrated vector was used to infect 2610
6 NIH3T3 cells in the
presence of 8.0 mg Polybrene ml
21, leading to nearly 100% GFP-
positive cells. Cells were subcultured three times at a 1:4 split every
3 days. Two days after the third split, approximately 100 ml
supernatant was collected and concentrated into 400 ml. Fresh
NIH3T3 cells were infected with the concentrated sample, maintained
in growth medium and checked for GFP-positive cells on days 3 and
7 p.i. Detection of GFP-positive cells was used as an indicator for
helper virus.
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PCR-based methods with primers 59-CTCGGCCTCTGCATAAAT-39
(forward) and 59-GATGAGTTTGGACAAACCAC-39 (reverse) which
amplified a 194 bp DNA fragment containing the SV40 ori sequence,
and primers 59-ATGGATAAAGTTTTAAACAGAGAG-39 (forward)
and 59-CTGAGCAAAACAGGTTTTC-39 (reverse), which amplified a
319 bp DNA fragment from the SV40T coding sequence were used
for the SV40T detection. To prepare PCR templates, 293T cells were
co-transfected as described, and CEM-SS cells were infected at an
m.o.i. of 100 with concentrated vector. DNAs were extracted by
digestion with protease K and RNase A at 56 uC for 3 h, phenol/
chloroform extraction and ethanol precipitation.
Transduction of human and mouse lymphocytes and macro-
phages. Initially, various cell lines were used to titrate vector aliquots
from the same preparation as described above. Subsequently,
2.0610
5 MT-2, BV-2, TIB-100 or RAW264.7 cells were infected
with concentrated vectors at an m.o.i. of 100 as described above. Cells
were then seeded in 25 cm
2 tissue culture flasks with growth medium,
and the percentage of GFP-positive cells was counted on day 3.
Primary MDMs were transduced on day 6 post-isolation using
concentrated vectors derived from MoMLV, HIV-1 and adenovirus.
For transduction with MoMLV-based vectors, cells were infected at
m.o.i. of 5, 10, 50 and 100. For HIV-1- and adenovirus-based vectors
and the SIN vectors, cells were infected at an m.o.i. of 100. Infected
cells were maintained in growth medium and photographed for GFP-
positive cells. The transduction efficiency was determined by counting
the percentage of GFP-positive cells.
Characterization of vector transduction by semi-quantitative
PCR. Concentrated MoMLV-based and DHIV-101 vectors were pre-
treated with DNase I (Promega) in 16 DNase I buffer for 30 min at
37 uC and then used to infect 2610
6 CEM-SS and RAW 264.7 cells at
an m.o.i. of 100. On day 1 p.i., 1.5610
6 cells were collected for DNA
extraction as described above. The remaining cells were cultured and
another 1.5610
6 cells were collected for DNA extraction on day
10 p.i. DNAs were diluted to 20 ng ml
21 and tenfold dilutions from
10
21 to 10
25 were made. PCR was performed in 25 ml reaction
volumes using GFP gene-specific primers 59-GGTGAGCAAGG-
GCGAGGAG-39 (forward) and 59-GCCGGTGGTGCAGATGAACT-
39 (reverse). One microlitre of each DNA dilution was added as
template, and 2 ng pDHIV-101 in 1 ml was used as a positive control
and 1 ml ddH2O as a negative control. Ten microlitres of each PCR
product was separated on a 2% agarose gel and photographed
following ethidium bromide staining. As an internal control, PCRs
with a pair of b-actin-specific primers [59-TGGTGGGCATGG-
GTCAGAAG-39 (forward) and 59-ACGCAGCTCATTGTAGAAGG-
TGTG-39 (reverse)] was performed under the same conditions, except
that an annealing temperature of 60 uC and 1 ng of a previously
obtained PCR product were used as template for positive controls.
CEM-SS and RAW 264.7 cells (1.5610
6 each) were infected with the
DHIV-101- or MoMLV-based vector at an m.o.i. of 100. At 24 h p.i.,
the cells were collected and the DNAs extracted as described above.
Detection of 2-LTR circle junctions was performed with a forward
primer annealing at the R region and a reverse primer annealing at
U3. Primers 59-GGGTCTCTCTGGTTAGACCAGATCT-39 (forward)
and 59-TATCTGATCCCTGGCCCTGGT-39 (reverse) were used for
HIV-1 2-LTR detection, and primers 59-CGCCAGTCCTCCGAT-
TGAC-39 (forward) and 59-TCTTTCATTCCCCCCTTTTTCTG-39
(reverse) for the detection of MoMLV 2-LTR. Both primer sets
amplified 2-LTR circle junctions of 295 bp. DNA templates were
diluted to 20 ng ml
21 and tenfold dilutions from 10
21 to 10
23 were
prepared. One microlitre from each template was used for reactions
in 25 ml volumes. The PCR product were separated and photographed
as described above.
Statistical analysis. Origin 6.0 professional software (OriginLab
Corp.) was used for two-population t-tests or one-way ANOVA.
P¡0.05 was considered statistically significant.
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